ESID-EHA-SIOPE Focused Symposium 2025

ESID-EHA-SIOPE Focused Symposium 2025 is organized by Kenes Group, European Society for Immunodeficiencies (ESID), European Hematology Association (EHA), European Society for Paediatric Oncology (SIOPE) and will be held from Nov 18 - 20, 2025 at Austria Center, Vienna, Wien, Austria.

Theme: ``The Interplay of Immunology & Haematology``

Why ESID-EHA-SIOPE 2025?
In recent years, the intersection between immunodeficiencies, haematologic conditions, and oncology has become ever more apparent. As we witness increasing complexity in patient diagnoses and treatments, the need for a collaborative, multidisciplinary approach is more critical than ever. This symposium aims to provide a comprehensive platform for exploring how immunodeficiencies can influence hematologic and oncologic conditions and vice versa, and how each specialty offers unique insights that contribute to improving diagnosis, treatment, and management strategies.

This symposium is an important opportunity for fellows, researchers and junior faculty to report and highlight novel basic and clinical information on this interplay of immunodeficiencies and malignant and non-malignant hematological diseases. They are encouraged to submit abstracts related to the keynote topics.

Our mission is simple: to unite our expertise across these vital fields to elevate patient care and outcomes.

This symposium marks a significant milestone in the collaboration between immunologists, haematologists, and paediatric oncologists.

What to Expect at ESID-EHA-SIOPE 2025?

• Multidisciplinary Insights: Dive into the pathophysiological links between immunodeficiencies, haematologic conditions, and oncologic disorders. Engage in discussions about the latest research, as well as best practices for diagnosis and integrated treatment approaches.
• Cross-Field Collaboration: This symposium will bring together experts from immunology, haematology, and oncology. It is a unique opportunity to learn from global leaders, exchange scientific ideas, and collaborate on new methods for improving patient care.
• Research and Scientific Discovery: We invite all researchers to submit abstracts and present their latest scientific findings. This is an excellent opportunity to contribute to the growing body of knowledge in this field and learn about cutting-edge research in immunodeficiencies, hematology, and oncology.

We believe that the ESID-EHA-SIOPE 2025 symposium will be an exciting and invaluable experience for all participants. This event is not only a platform for sharing knowledge but also a celebration of the collective effort of three societies—ESID, EHA, and SIOPE—coming together for one mission: advancing patient care through collaboration and innovation.

Educational Objectives:
After participating in this educational event, learners should be able to:

• Integrate newly acquired knowledge into their Continuous Professional Development (CPD) plan, addressing individual learning needs.
• Evaluate the pathophysiological links between autoimmune hematology, immunodeficiencies, and malignancies to enhance integrated diagnostic and treatment strategies.
• Analyze the diagnostic approaches in hematology, immunology, and histopathology for complex immunodeficiency-related lymphoproliferative disorders.
• Identify the genetic and somatic factors contributing to genetically determined cytopenia and bone marrow failure syndromes to improve patient diagnosis and management.
• Apply knowledge of monogenic syndromes in hematopoiesis to deepen understanding of hematologic malignancies and disorders.
• Compare the different treatment strategies for hematological alloimmunity, including approaches in allogeneic HSCT, platelet alloimmunity, and neonatal hematology.
• Assess the role of immune deficiencies in predisposing individuals to malignancy and understand new genes and mechanisms involved in cancer predisposition.
• Discuss the management of secondary immune disorders (SID) in patients undergoing CAR T cell therapy, and explore treatment options beyond CAR T.
• Develop an understanding of treatment protocols for malignancies in immunocompromised patients, including children with PID and patients with AT, to improve therapeutic decision-making.